1-10 of 10
intermittent claudication
Close
Sort by
Journal Articles

Inducible MyD88 Signaling Enhances the Anti-AML Activity of BiTE-Secreting ENG T-Cells

Abishek Vaidya, MS, Erin E Doherty, MD, Xiya Wu, Challice L. Bonifant, MD PhD, Stephen Gottschalk, MD, Mireya Paulina Velasquez, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4441.
https://doi.org/10.1182/blood-2019-125395
Published: 2019
Journal Articles

Acute Common Iliac Artery Thrombosis with Concurrent Pulmonary Embolism Revealing AML M2: Role of Elevated Plasma Tissue Factor Activity

Hind Bennani, PharmD, Raphaël Coscas, MD, Marc Coggia, MD, Patrick Van Dreden, PhD, Marc Vasse, PharmD, Jacques Vargaftig, MD
Journal: Blood
Blood (2015) 126 (23): 4722.
https://doi.org/10.1182/blood.V126.23.4722.4722
Published: 2015
Journal Articles

CITED2 Cooperates with Low PU.1 and DNMT3A to Maintain Self-Renewal in Hematopoietic Stem Cells

Hein Schepers, PhD, Patrick Korthuis, MSc, Marjan Geugien, MSc, Jennifer Jaques, MSc, Tihomira I. Todorova, MSc, Ulrich Steidl, MD PhD, Jan Jacob Schuringa, PhD, Edo Vellenga, MD PhD
Journal: Blood
Blood (2015) 126 (23): 309.
https://doi.org/10.1182/blood.V126.23.309.309
Published: 2015
Journal Articles

Economic Burden of Adverse Events Among Patients with Chronic Myelogenous Leukemia Treated with BCR-ABL1 Tyrosine Kinase Inhibitors

Jay Lin, PhD MBA, Makenbaeva Dinara, MD MBA, Bilmes Robyn, PharmD, BCOP, Melissa Lingohr-Smith, PhD, Nicola Wallis, MRCPath, FFPM
Journal: Blood
Blood (2015) 126 (23): 876.
https://doi.org/10.1182/blood.V126.23.876.876
Published: 2015
Journal Articles

The Effect of the R882H DNMT3a Mutation on Megakaryocyte Cell Lines

Yang Lu, MD, Dan Wang, Yifang Yuan, Li mei Chen, Yi ke Huang, Hao Huang, MD, Kefeng Shen, MD, Yanyan Ye, Jing Sun, MD, Qianli Jiang, MD PhD
Journal: Blood
Blood (2014) 124 (21): 5186.
https://doi.org/10.1182/blood.V124.21.5186.5186
Published: 2014
Journal Articles

Peripheral Arterial Occlusive Disease (PAOD) In Patients (Pts) Receiving Dasatinib: Experience Across Multiple Clinical Trials

Philipp D. le Coutre, MD, Timothy P. Hughes, MD, MBBS, Francois-Xavier Mahon, Dong-Wook Kim, Juan Luis Steegmann, Neil P. Shah, MD, PhD, Nicola Wallis, Jorge E. Cortes, MD
Journal: Blood
Blood (2013) 122 (21): 1489.
https://doi.org/10.1182/blood.V122.21.1489.1489
Published: 2013
Journal Articles

CITED2 Modulates Differentiation and Proliferation of Normal and Leukemic Hematopoietic Stem and Progenitor Cells Downstream of PU.1

Hein Schepers, Ph.D, Patrick M. Korthuis, Jan J. Schuringa, PhD, Gerald de Haan, Ph.D, Edo Vellenga, PhD
Journal: Blood
Blood (2011) 118 (21): 922.
https://doi.org/10.1182/blood.V118.21.922.922
Published: 2011
Journal Articles

Retrospective Cohort Analysis of Peripheral Arterial Occlusive Disease (PAOD) Events in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Francis J. Giles, MB, MD, FRCPI, FRCPath, Michael J. Mauro, MD, Frank Hong, MD, PhD, MPH, Christine-Elke Ortmann, Richard C. Woodman, Philipp D. LeCoutre, MD, Giuseppe Saglio, MD
Journal: Blood
Blood (2011) 118 (21): 2757.
https://doi.org/10.1182/blood.V118.21.2757.2757
Published: 2011
Journal Articles

Comparison of Adverse Drug Reactions for Patients Treated with Tyrosine Kinase Inhibitors: Data Mining of the Public Version of the FDA Adverse Event Reporting System (AERS)

Tetsuya Tanimoto, MD, Yasuo Oshima, MD, PhD, FACP, Koichiro Yuji, M.D., Ph.D., Masahiro Kami, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 1698.
https://doi.org/10.1182/blood.V118.21.1698.1698
Published: 2011
Journal Articles

Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes

Concetta Quintarelli, Juan F. Vera, Barbara Savoldo, Greta M. P. Giordano Attianese, Martin Pule, Aaron E. Foster, Helen E. Heslop, Cliona M. Rooney, Malcolm K. Brenner, Gianpietro Dotti
Journal: Blood
Blood (2007) 110 (8): 2793–2802.
https://doi.org/10.1182/blood-2007-02-072843
Published: 2007
Includes: Supplemental data